Ginkgo Bioworks Holdings, Inc. DNA
We take great care to ensure that the data presented and summarized in this overview for Ginkgo Bioworks Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DNA
View all-
Baillie Gifford & CO233MShares$189 Million0.21% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl190MShares$154 Million1.57% of portfolio
-
Viking Global Investors LP143MShares$116 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA126MShares$102 Million0.0% of portfolio
-
Black Rock Inc. New York, NY72.9MShares$59 Million0.0% of portfolio
-
Anchorage Capital Group, L.L.C. New York, NY69.9MShares$56.6 Million21.46% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.55.9MShares$45.3 Million0.05% of portfolio
-
Nikko Asset Management Americas, Inc.55.9MShares$45.3 Million0.65% of portfolio
-
Morgan Stanley New York, NY49.1MShares$39.7 Million0.0% of portfolio
-
State Street Corp Boston, MA26.6MShares$21.5 Million0.0% of portfolio
Latest Institutional Activity in DNA
Top Purchases
Top Sells
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Insider Transactions at DNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Shyam Sankar Director |
BUY
Open market or private purchase
|
Direct |
625,000
+20.96%
|
$0
$0.82 P/Share
|
|
May 14
2024
|
Harry Sloan Director |
BUY
Open market or private purchase
|
Direct |
297,619
+29.29%
|
$0
$0.91 P/Share
|
|
May 14
2024
|
Marijn E Dekkers Director |
SELL
Open market or private sale
|
Direct |
1,727,056
-86.0%
|
$0
$0.93 P/Share
|
|
May 02
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
47,806
-4.91%
|
$0
$0.84 P/Share
|
|
May 02
2024
|
Steven P. Coen Officer |
SELL
Open market or private sale
|
Direct |
131,928
-44.8%
|
$0
$0.84 P/Share
|
|
May 01
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
108,127
+2.73%
|
-
|
|
May 01
2024
|
Steven P. Coen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
294,455
+27.04%
|
-
|
|
Apr 02
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
51,169
-5.58%
|
$51,169
$1.05 P/Share
|
|
Apr 01
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
108,123
+2.9%
|
-
|
|
Mar 04
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
38,826
-4.58%
|
$38,826
$1.26 P/Share
|
|
Mar 01
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
85,214
+3.21%
|
-
|
|
Feb 02
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
39,569
-4.94%
|
$39,569
$1.21 P/Share
|
|
Feb 01
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
85,208
+3.38%
|
-
|
|
Jan 04
2024
|
Jason R Kelly Director |
SELL
Open market or private sale
|
Direct |
100,000
-2.5%
|
$100,000
$1.55 P/Share
|
|
Jan 03
2024
|
Jason R Kelly Director |
SELL
Open market or private sale
|
Direct |
100,000
-2.44%
|
$100,000
$1.54 P/Share
|
|
Jan 03
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
45,794
-6.01%
|
$45,794
$1.54 P/Share
|
|
Jan 02
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
85,048
+3.54%
|
-
|
|
Dec 21
2023
|
Reshma P. Shetty Director |
SELL
Open market or private sale
|
Indirect |
37,650
-0.3%
|
$37,650
$1.74 P/Share
|
|
Dec 21
2023
|
Jason R Kelly Director |
SELL
Open market or private sale
|
Direct |
100,000
-2.38%
|
$100,000
$1.74 P/Share
|
|
Dec 21
2023
|
Barry Canton > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
37,650
-0.3%
|
$37,650
$1.74 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.67M shares |
|---|---|
| Exercise of conversion of derivative security | 1.36M shares |
| Conversion of derivative security | 400K shares |
| Open market or private sale | 13.9M shares |
|---|---|
| Bona fide gift | 400K shares |